Skip to main content
logo
Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.35
+0.07 (0.58%)
Oct 26, 2026, 2:16 PM EDT - Market open

Keros Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
15.01244.063.550.15-20.1
Revenue Growth
-93.55%6774.96%2250.99%---
Gross Profit
-58.35116.92-170.08-135.11-87.27-35.04
Operating Income
-98.4770.57-210.83-169.94-114.79-56.37
Net Income
-83.1687.01-187.35-152.99-104.68-58.74
Earnings Per Share
-3.102.30-5.00-5.20-4.15-2.52
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
257.61287.42559.93331.15279.05230.04
Total Debt
15.7216.8818.8614.4413.271.09
Net Cash (Debt)
241.88270.53541.07316.7265.78228.95
Net Cash Growth
-64.02%-50.00%70.84%19.16%16.09%-13.60%
Net Cash Per Share
9.037.1514.4510.7510.539.81

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-47.99107.51-160.87-124.51-70.06-62.15
Capital Expenditures
-0.49-1.55-1.93-2.46-1.24-1.02
Free Cash Flow
-48.49105.95-162.8-126.97-71.3-63.17
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-47.91%----174.34%
Operating Margin
-655.84%28.91%-5938.96%-112543.71%--280.46%
Pretax Margin
-573.44%37.65%-5269.10%-101319.21%--282.25%
Profit Margin
-553.88%35.65%-5277.55%-101319.21%--292.26%
FCF Margin
-322.94%43.41%-4585.91%-84087.42%--314.29%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-7.13----
P/FCF Ratio
-5.85----
PS Ratio
15.032.54180.637888.64-68.11